Table 1.

The comparison of 24 months survival and galectin-3 expression in selected groups of patients.

Survival	Positive galectin-3 expression n (%)	Negative galectin-3 expression n (%)	Chi2 Yatesa	p	Cox Mantel
All examinated patients with NSCLC
< 24 months	8 (44.44%)	12 (41.38%)	0.01	0.922	0.841
≥ 24 months	10 (55.56%)	17 (58.62%)
The patients with squamous cell carcinoma
< 24 months	5 (45.45%)	5 (38.46%)	0.00	0.944	0.612
≥ 24 months	6 (54.55%)	8 (61.54%)
The patients with adenocarcinoma
< 24 months	2 (50%)	6 (54.55%)	0.18	0.667	0.695
≥ 24 months	2 (50%)	5 (45.45%)
Stage I
< 24 months	1 (33.33%)	2 (14.29%)	0.00	0.960	0.434
≥ 24 months	2 (66.66%)	12 (85.71%)
Stage II
< 24 months	2 (40%)	3 (100%)	0.89	0.345	0252
≥ 24 months	3 (60%)	0 (0%)
Stage III
< 24 months	2 (28.57%)	5 (55.56%)	0.33	0.567	0.275
≥ 24 months	5 (71.43%)	4 (44.44%)
Stage IV
< 24 months	3 (100%)	2 (66.67%)	0.00	1.00	0.341
≥ 24 months	0 (0%)	1 (33.33%)